Core Points - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7] - The lawsuit covers individuals who purchased Baxter common stock between February 23, 2022, and October 29, 2025, with a deadline of December 15, 2025, for investors to apply as lead plaintiffs [7] Allegation Details - The complaint claims that Baxter failed to disclose critical information about the Novum LVP, including systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [3] - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures, leading to continued harm [3] - The lawsuit suggests that Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were materially false and misleading [3] Next Steps - Investors who suffered losses and wish to learn more about the claims or have questions are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for further information [4] - The firm emphasizes that there is no cost or obligation for investors to inquire about their rights [4] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation across state and federal courts [5]

Core Viewpoint - Baxter International, Inc. is facing a securities fraud class action lawsuit due to serious safety issues related to its Novum IQ Large Volume Pump, which has been linked to patient injuries and deaths, leading to a significant drop in stock price [1][4][5]. Group 1: Incident Overview - On April 7, 2025, a Missouri news outlet reported safety issues with Baxter's Novum LVP, claiming it was unsafe for patient treatment based on a whistleblower's information [2]. - Baxter issued warning letters on April 24 and July 14, 2025, regarding underinfusion and overinfusion risks, revealing 79 reports of serious injuries and two patient deaths associated with the device [3]. - The FDA classified the issues with Novum LVP as a Class I recall, indicating a severe risk of injury or death [3]. Group 2: Stock Impact - Following the announcement of a voluntary pause in shipments and installations of the Novum LVP on July 31, 2025, Baxter's stock price fell by $6.24, or 22.4%, closing at $21.61 per share [4]. Group 3: Lawsuit Details - The lawsuit alleges that Baxter made false or misleading statements regarding the safety and functionality of the Novum LVP, failing to disclose systemic defects and the risks associated with the device [5]. - It is claimed that Baxter was aware of multiple malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of customers removing the devices from service [5].

Core Viewpoint - The complaint against Baxter International alleges violations of federal securities laws due to misleading statements regarding the Novum LVP, which suffered systemic defects leading to serious patient risks [2]. Group 1: Allegations and Defects - The Novum LVP experienced systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects but failed to adequately address them [2]. - The company's attempts to remedy the situation through customer alerts were deemed insufficient as design flaws persisted, continuing to harm patients [2]. Group 2: Impact on Business Operations - Due to the defects, there was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter would halt all new sales of these pumps [2]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were materially false and misleading [2]. Group 3: Market Reaction - The extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, leading to a 22.4% drop in stock price, closing at $21.76 on the same day [3].

Core Insights - Dr. Walter Jacobson's comedy film "Baxter's Brain" achieved 3rd place at the American Film Market (AFM) Pitch Conference, showcasing its potential appeal in the film industry [1][4] Group 1: Film and Industry Context - The AFM Pitch Conference is a prominent platform where selected creators present their projects to industry professionals, highlighting the competitive nature of film development [3] - Dr. Jacobson transitioned from psychiatry back to screenwriting after 25 years, indicating a blend of life experience and creative storytelling [4] Group 2: Film Concept and Audience Appeal - "Baxter's Brain" is described as a satirical comedy that critiques societal norms and the medical profession, suggesting a unique angle that may resonate with audiences [4] - The film features a super-smart, talking gorilla, which aligns with successful comedic trends seen in films like "TED" and "Paddington," indicating a strategic choice to attract a broad audience [5] Group 3: Confidence and Future Plans - Dr. Jacobson's confidence in the screenplay stems from his extensive study of comedy and past experiences in the entertainment industry, suggesting a strong foundation for the film's success [6] - The next steps involve securing financing and production, with hopes that media coverage will attract potential investors and collaborators [6]

With a market cap of $9.4 billion, Baxter International Inc. (BAX) is a global medical technology company specializing in essential hospital products and therapies used in intensive care, kidney care, pharmaceuticals, and surgical settings. Headquartered in Deerfield, Illinois, its portfolio spans infusion systems, dialysis equipment, sterile IV solutions, and advanced patient monitoring technologies. Companies worth $10 billion or more are generally described as “large-cap stocks,” and BAX perfectly fit ...

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [3][4]. Group 1: Allegations and Issues - The complaint alleges that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly notified of multiple device malfunctions, injuries, and deaths related to these defects, indicating a significant awareness of the issues [3]. - The company's attempts to address these defects through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - There is a heightened risk that customers may be instructed to take existing Novum LVPs out of service, and Baxter may pause all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 23, 2022, to October 29, 2025, with a deadline for shareholders to register by December 15, 2025 [3][4]. - Shareholders who purchased shares during the class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment, although this is not required for recovery [1][4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4].

Core Insights - Baxter International Inc. announced positive data regarding the integration of smart infusion pumps with hospital electronic medical records (EMRs), highlighting improvements in patient safety, clinician productivity, and programming compliance [1] Group 1: Company Impact - The collaboration with The University of Texas Medical Branch (UTMB Health) analyzed over one million infusions, demonstrating the effectiveness of Baxter's Spectrum IQ infusion system [1]

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Baxter (BAX) To Contact Him Directly To Discuss Their Options If you purchased or Baxter common stock between February 23, 2022 and July 30, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel ...

Core Insights - Pzena Investment Management's third-quarter 2025 commentary indicates a strong performance in US broad-based indexes driven by optimism about AI and a September rate cut, with the technology sector outperforming value stocks [1] - The Pzena Focused Value strategy returned 1.1% gross and 0.9% net, underperforming the Russell 1000 Value Index which returned 5.3% [1] Company Overview: Baxter International Inc. (NYSE:BAX) - Baxter International Inc. is a healthcare company with a market capitalization of $9.335 billion, and its stock closed at $18.48 per share on December 09, 2025 [2] - The stock experienced a one-month return of -2.89% and a significant decline of 41.42% over the last 52 weeks [2] Performance Analysis - Baxter's disappointing performance in the third quarter was attributed to a voluntary recall of a recent product launch and a slower-than-expected recovery in demand for IV fluids, which were disrupted by Hurricane Helene [3] - Despite these challenges, the Pzena Focused Value Strategy views the stock price reaction as disproportionate and has increased its position in Baxter [3] Hedge Fund Interest - Baxter International Inc. was held by 38 hedge fund portfolios at the end of the third quarter, an increase from 31 in the previous quarter [4] - While Baxter is recognized for its potential, analysts suggest that certain AI stocks may offer greater upside potential with less downside risk [4] Market Sentiment - The SCCM Enhanced Equity Income Fund divested its stake in Baxter during Q3 2025, indicating a shift in investment strategy among some funds [5]

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2] - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2] - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2] - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2] - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses in Baxter International, Inc. during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]